

EVS BROADCAST EQUIPMENT SA Liège Science Park 13, rue Bois St-Jean

B- 4102 Seraing - Belgium Phone. +32 4 361 7000 - Fax +32 4 361 7089

Company number: 0452.080.178 (RPM Liège)

www.evs.com

For information purpose only – unofficial translation – French original wording prevails

NOTICE CONVENING THE ORDINARY GENERAL MEETING OF SHAREHOLDERS AND AN EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS

The **ordinary general meeting** of EVS Broadcast Equipment SA (the "<u>Company</u>") will be held on **Tuesday May 16, 2023**, at 11:00 am (the "<u>Ordinary General Meeting</u>") and an **extraordinary general meeting** of the Company will be held on **Tuesday May 16, 2023**, at 12:00 pm (the "<u>Extraordinary General Meeting</u>"), before France Andris, LLM, notary of Bassenge, at the Company's headquarters at the following address: 13, rue Bois Saint-Jean, B-4102 Seraing (together, the "<u>General Meetings</u>").

- The General Meetings will be held physically at the Company's registered office in accordance with the Company's Articles of Association.
- The Board of Directors has not opted for the possibility of allowing shareholders to participate remotely via electronic communication as offered by article 7:137 of the Belgian Companies and Associations Code (the "CAC"). However, it will allow shareholders to follow the Ordinary General Meeting by means of a videoconference or audioconference system, the details of which will be specified on the Company's website. This system will not allow shareholders to participate, vote or interact in the Ordinary General Meeting.

Accompanying documents

Shareholders' attention is drawn to the accompanying documents published by the Board of Directors on the Company's website (https://evs.com/company/general-meetings) together with this convocation, including:

- (i) the statutory and consolidated annual report of the Board of Directors;
- (ii) the proposed updated Remuneration Policy of the Company;
- (iii) the special reports of the Board of Directors and of the Auditor on the authorized capital and on the issue of warrants; and
- (iv) an explanatory note in relation to the agenda items of the Extraordinary General Meeting concerning the authorized capital and the issue of warrants.

Shareholders should review these documents for the purpose of being fully informed on the agenda items of the General Meetings and the rationale behind the decisions proposed by the Board of Directors.

Agenda of the Ordinary General Meeting:

Quorum and majority

The resolutions of this Ordinary General Meeting do not require a special quorum and require a simple majority of the votes cast at the Ordinary General Meeting to be adopted.

Agenda items

- Acknowledgement of the Management Report relating to the statutory and consolidated annual accounts for the financial year ended on December 31, 2022 in which is included the Company's Corporate Governance Statement and the Sustainability Report, drawn up by the Board of Directors.
- 2. Presentation and approval of the Remuneration Report for the financial year ended on December 31, 2022, included in the Corporate Governance Statement of the Management Report.
 - The Board of Directors acknowledges the result of the vote on the Remuneration Report in previous general meetings. The Board of Directors acknowledges the importance of this feedback from shareholders and has chosen to take action through the review of the structure and the content of the remuneration report (i) by increasing the level of disclosure in terms of performance metrics with regard to the variable remuneration of the members of the Executive Management and by (ii) explaining the reasons

why the Company is deviating from the CAC in terms of variable remuneration of the members of the Executive Management, while aiming at gradually aligning their long-term incentive with performance and multi-year objectives.

<u>Proposed decision</u>: the general meeting approves the Remuneration Report for the financial year ended on December 31, 2022, included in the Corporate Governance Statement of the Management Report.

- **3. Acknowledgement of the Auditor's Reports** relating to the statutory and consolidated annual accounts for the financial year ended on December 31, 2022.
- 4. Presentation and approval of the statutory and consolidated annual accounts for the financial year ended December 31, 2022, and the allocation of results; presentation and approval of the profit-sharing plan in the form of a distribution of shares to the Company's employees.

<u>Proposed decision</u>: the general meeting approves the statutory accounts for the financial year ended on December 31, 2022 and the allocation of the net profit of EUR 59.857.014,64 as follows:

- distribution of a gross dividend of EUR 1.60 per share, which corresponds to a total of EUR 21,470,416 based on the total number of shares outstanding of 13,419,010 on 31/12/2022, of which (i) a portion of EUR 0.50 gross per existing share has been paid in November 2022 (coupon 33) by way of interim dividend and (ii) the balance of EUR 1.10 gross per share will be payable upon detachment of the coupon 34.
- distribution of 42 shares of the Company to each employee of the Company which has been hired before January 1, 2023, in proportion to its effective services (or equivalent) in 2022, under the profit-sharing plan relating to the distribution of the profits of the financial year ending on December 31, 2022, which is hereby approved. The grant of such shares by the Company, subject to compliance with its tax obligations, is equally approved. This plan concerns a maximum of 393 persons;
- carry over the balance of the net profit, after any deductions imposed by law or the articles of association, to the next financial year.

5. Discharge to the Directors

<u>Proposed decision</u>: the general meeting discharges the Directors from any liability resulting from the performance of their mandate during the past financial year.

6. Discharge to the Auditor

<u>Proposed decision</u>: the general meeting discharges the Auditor from all liability resulting from the performance of his mandate during the past financial year.

- 7. Renewal of the mandate of Accompany You SRL, represented by Mrs. Anne Cambier, as Director Proposed decision: The general meeting takes note of the end of the mandate of Accompany You SRL as Director of the Company and decides to renew the mandate of Accompany You SRL, represented by Mrs. Anne Cambier, as Director for a period of four years ending at the end of the ordinary general meeting of May 2027, and acknowledges its independence, in accordance with Article 7:87 of the CAC, as it meets the definition of this article and fulfils all the criteria set out in the Belgian Corporate Governance Code 2020. The mandate is remunerated in accordance with the Remuneration Policy applicable to all members of the Board of Directors.
- 8. Appointment of InnoVision BV, represented by Mr. Serge Van Herck, as Director <u>Proposed decision</u>: The general meeting appoints InnoVision BV, represented by Mr. Serge Van Herck, as Director for a period of four years ending at the end of the ordinary general meeting of May 2027. The remuneration or not of the mandate is subject to the Remuneration Policy applicable to all members of the Board of Directors.
- 9. Appointment of FRINSO SRL, represented by Mrs. Soumya Chandramouli, as Director Proposed decision: The general meeting appoints FRINSO SRL, represented by Mrs. Soumya Chandramouli, as Director for a period of four years ending at the end of the ordinary general meeting of May 2027, and acknowledges its independence in accordance with article 7:87 of the CAC, since it meets the definition of that article and fulfils all the criteria set out in the Belgian Corporate Governance Code 2020. The mandate is remunerated in accordance with the Remuneration Policy applicable to all members of the Board of Directors.

10. Approval of updates to the Remuneration Policy

The Board of Directors acknowledges the result of the vote on the Remuneration Policy in previous general meetings. The Board of Directors acknowledges the importance of this feedback from shareholders and has chosen to take action by proposing updates to the Remuneration Policy last approved on May 17, 2022 that increase transparency towards shareholders and are in line with market standards. The proposed amended Remuneration Policy is appended to this convocation. The updates

which we consider important, and which are the subject of separate agenda items and proposed decisions, are as follows:

- Amendment of the remuneration of the executive Directors as they will no longer be remunerated with effect as of 1 January 2023.
- Amendment of the variable remuneration of the following members of the Executive Management (Leadership Team), including deviations of article 7:91, §2 in combination with article 7:121 of the CAC:
 - Cash-based short-term incentive (STI) of the CFO, CMO, CPO, CTO, CXO and CCO;
 - o Long-term incentive (LTI) by way of grant of warrants to the CFO, CTO and CXO;
 - Cash-based short-term incentive (STI) of, and long-term incentive (LTI) by way of grant of warrants to, the CEO; and
 - Introduction of a procedure to allow deviations from the Remuneration Policy in accordance with the conditions set out in the CAC.

The Board of Directors has adopted the proposed amended Remuneration Policy on March 31, 2023, subject to and to the extent that the proposed resolutions 10.1 to 10.5 respectively are approved by the Ordinary General Meeting.

10.1 Removal of the remuneration of the executive Directors

The Board of Directors proposes that the executive members of the Board of Directors shall no longer receive any remuneration in their capacity of members of the Board of Directors as of January 1, 2023. This is proposed in order to align with Belgian market standards.

<u>Proposed decision</u>: The general meeting decides that as of January 1, 2023, the executive members of the Board of Directors shall no longer receive any remuneration.

10.2 Approval of variable remuneration in cash of the CFO, CMO, CPO, CTO, CXO and CCO

The Board of Directors proposes to approve the potential variable remuneration in cash of the Chief Financial Officer (CFO), Chief Marketing Officer (CMO), Chief People Officer (CPO), Chief Technology Officer (CTO), Chief Experience Officer (CXO) and Chief Customer Officer (CCO), in accordance with article 7:91, §2 in combination with article 7:121 of the CAC.

This concerns the services agreements entered into between the Company and WeMagine SRL (represented by Mrs. Veerle De Wit), Ikaro SRL (represented by Mr. Nicolas Bourdon), M2C SRL (represented by Mr. Pierre Matelart), Openiris Ltd (represented by Mr. Alexander Redfern), Tols BV (represented by Mr. Xavier Orri Sáinz De Los Terreros) and RCG SRL (represented by Mr. Quentin Grutman) relating to the position, respectively, of CFO, CMO, CPO, CTO, CXO and CCO. The formula for the calculation of the variable remuneration in cash under these agreements slightly deviates from the formula provided for in article 7:91, §2 of the CAC. Details on the calculation of such variable remuneration are included in the proposed amended Remuneration Policy under section 2.8.

<u>Proposed decision</u>: The general meeting expressly approves, in accordance with article 7:91, §2 and 7:121 of the CAC, the derogation from the criteria set out in article 7:91, §2 of the CAC regarding the variable remuneration in cash allocated to WeMagine SRL (represented by Mrs. Veerle De Wit), Ikaro SRL (represented by Mr. Nicolas Bourdon), M2C SRL (represented by Mr. Pierre Matelart), Openiris Ltd (represented by Mr. Alexander Redfern), Tols BV (represented by Mr. Xavier Orri Sáinz De Los Terreros) and RCG SRL (represented by Mr. Quentin Grutman) in their capacity of Chief Financial Officer (CFO), Chief Marketing Officer (CMO), Chief People Officer (CPO), Chief Technology Officer (CTO), Chief Experience Officer (CXO) and Chief Customer Officer (CCO), as agreed (subject to approval by the general meeting in accordance with Article 7:91, §2 of the CAC) between the Company and each of the abovementioned members of the Executive Management in their services agreement.

10.3 Approval of variable remuneration by way of grant of warrants to the CFO, CTO and CXO

The Board of Directors proposes to approve the potential variable remuneration by way of grant of warrants to the Chief Financial Officer (CFO), Chief Technology Officer (CTO) and Chief Experience Officer (CXO), in accordance with article 7:91, §2 in combination with article 7:121 of the CAC.

This concerns the services agreements entered into between the Company and WeMagine SRL (represented by Mrs. Veerle De Wit), Openiris Ltd (represented by Mr. Alexander Redfern) and Tols BV (represented by Mr. Xavier Orri Sáinz De Los Terreros) relating to the position, respectively, of CFO, CTO and CXO. The formula for the calculation of the variable remuneration by way of grant of warrants under these agreements slightly deviates from the formula provided for in article 7:91, §2 of the CAC. Details on the calculation of such variable remuneration are included in the proposed amended Remuneration Policy under section 2.8.

<u>Proposed decision</u>: The general meeting expressly approves, in accordance with article 7:91, §2 and 7:121 of the CAC, the derogation from the criteria set out in article 7:91, §2 of the CAC regarding the variable remuneration by way of grant of warrants allocated to WeMagine SRL (represented by Mrs. Veerle De Wit), Openiris Ltd (represented by Mr. Alexander Redfern) and Tols BV (represented by Mr. Xavier Orri Sáinz De Los Terreros) in their capacity of Chief Financial Officer (CFO), Chief Technology

Officer (CTO) and Chief Experience Officer (CXO), as agreed (subject to approval by the general meeting in accordance with Article 7:91, §2 of the CAC) between the Company and each of the abovementioned members of the Executive Management in their services agreement.

10.4 Approval of variable remuneration in cash of, and by way of grant of warrants to, the CEO

The Board of Directors proposes to approve (i) the potential variable remuneration in cash of, and (ii) the potential variable remuneration by way of grant of warrants to, the Chief Executive Officer (CEO), in accordance with article 7:91, §2 in combination with article 7:121 of the CAC.

This concerns the services agreement entered into between the Company and InnoVision BV (represented by Mr. Serge Van Herck) relating to the position of CEO. The formula for the calculation of the variable remuneration in cash and by way of grant of warrants under this agreement slightly deviates from the formula provided for in article 7:91, §2 of the CAC. Details on the calculation of such variable remuneration are included in the proposed amended Remuneration Policy under section 2.8.

<u>Proposed decision</u>: The general meeting expressly approves, in accordance with article 7:91, §2 and 7:121 of the CAC, the derogation from the criteria set out in article 7:91, §2 of the CAC regarding the variable remuneration in cash and by way of grant of warrants allocated to InnoVision BV (represented by Mr. Serge Van Herck), in its capacity of Chief Executive Officer (CEO), as agreed (subject to approval by the general meeting in accordance with Article 7:91, §2 of the CAC) between the Company and InnoVision BV in its services agreement.

10.5 Introduction of a procedure to allow deviations from the Remuneration Policy

The Board of Directors proposes to introduce in the Remuneration Policy a procedure to allow deviations from the Remuneration Policy in accordance with the conditions set out in article 7:89/1 of the CAC. In accordance with such article, any deviation would be possible only temporarily if necessary to serve the long-term interests and sustainability of the Company, upon the request of the Nomination and Remuneration Committee. It is proposed to introduce this deviation procedure only in limited circumstances, in order to allow the Board of Directors to grant a stand-alone bonus to members of the Executive Management based on secured order intake of more than 5 years or order intake related to Big Event Rental, in both cases capped to a maximum percentage of 0,2% of the relevant order intake (as further set out in the proposed amended Remuneration Policy under section 2.5). The Board of Directors considers that such deviation procedure is in line with market practice for Belgian listed companies and will make it possible to reward exceptional performance and retain key executive members in the interest of the Company's sustained success in the long term.

<u>Proposed decision</u>: The general meeting approves the introduction of a procedure to allow deviations from the Remuneration Policy, in accordance with article 7:89/1 of the CAC and on the terms set out in the proposed revised Remuneration Policy.

11. Powers to execute the decisions taken

<u>Proposed decision</u>: The general meeting confers on each member of the Board of Directors, with the right of substitution, all powers of execution of the decisions taken by the Ordinary General Meeting as well as all powers for the purpose of carrying out the formalities necessary for their publication.

Agenda of the Extraordinary General Meeting:

Quorum and majority

The resolutions of this Extraordinary General Meeting require the representation of at least half of the capital of the Company (except if a second Extraordinary General Meeting is convened with the same agenda, should this Extraordinary General Meeting fail to obtain such quorum, in which case decisions can be taken regardless of the portion of the capital present or represented) and a majority of three quarters of the votes cast at the Extraordinary General Meeting, except for resolution 3, which does not require any particular quorum and require a simple majority of the votes cast at the Extraordinary General Meeting to be adopted.

In the event that this Extraordinary General Meeting cannot be held due to a lack of quorum, a second Extraordinary General Meeting shall be held on June 5, 2023 at 12:00 pm at the Company's registered office.

Agenda items

1. Approval of the authorized capital up to a maximum amount of EUR 1,600,000 (or EUR 877,200), excluding share premium

- a) Acknowledgement of the special report of the Board of Directors prepared in accordance with article
 7:198 and following of the CAC in which it indicates the specific circumstances in which it may use the authorized capital and the objectives it will pursue in doing so.
- b) Proposal to authorize, in accordance with article 7:198 and following of the CAC, the Board of Directors in article 7 of the Articles of Association, to increase the capital of the Company on one or more occasions up to a maximum amount of EUR 1,600,000, excluding the issue premium, all other conditions remaining unchanged, for a period of five (5) years from the date of publication in the Appendices to the Belgian Official Gazette of the minutes of the Extraordinary General Meeting (as may be re-scheduled in case of lack of quorum).
- c) If proposal 1.b) does not obtain the required majority, proposal to grant, in accordance with article 7:198 and following of the CAC, an authorization to the Board of Directors to increase the capital of the Company in one or more instalments up to a maximum amount of EUR 877,200, excluding issue premium, all other conditions provided for in the current article 7 of the Articles of Association remaining unchanged, for a further period of five (5) years from the publication in the Appendices to the Belgian Official Gazette of the resolution of the Extraordinary General Meeting (as may be rescheduled in case of lack of quorum).

<u>Proposed decision</u>: The general meeting decides to replace article 7 of the Articles of Association by the following text:

"Authorized capital

[Under proposal 1.b):] Pursuant to a resolution passed by the extraordinary general meeting of shareholders of May 16, 2023 (or June 5, 2023), the Board of Directors is authorized to increase the capital in one or more occasions up to a maximum amount of ONE MILLION SIX HUNDRED THOUSAND EUROS (EUR 1,600,000), excluding the share premium.

[Under proposal 1.c):] Pursuant to a resolution passed by the extraordinary general meeting of shareholders of May 16, 2023 (or June 5, 2023), the Board of Directors is authorized to increase the capital in one or more instalments up to a maximum amount of EIGHT HUNDRED SEVENTY-SEVEN THOUSAND TWO HUNDRED EUROS (EUR 877,200), excluding the share premium.

These capital increases may be carried out by subscriptions in cash, contributions in kind, or incorporation of reserves or issue premiums, with or without the creation of shares.

Within the limits of this authorization, the Board of Directors may issue bonds convertible into shares or subscription rights, in compliance with the provisions of articles 7:198 et seq. of the Companies and Associations Code.

In the case of a share capital increase with share premium, such premium must be entered and maintained in one or more separate accounts under shareholders' equity on the liabilities side of the balance sheet.

Similarly, in the event of an issue of subscription rights, their issue price must be entered and maintained in one or more separate accounts under shareholders' equity on the liabilities side of the balance sheet.

On the occasion of any issue of shares, convertible bonds or subscription rights, the Board of Directors may limit or cancel the preferential subscription rights of the shareholders, including in favour of one or more specific persons other than staff members, in accordance with the terms and conditions to be determined by the Board of Directors and subject to compliance with the provisions of articles 7:198 et seq. of the Belgian Companies and Associations Code.

This general authorization is valid for a period of five (5) years from the publication of the resolution of May 16, 2023 (or June 5, 2023) and is renewable.

The Board of Directors shall be entitled to amend the Articles of Association to the extent required to reflect the use of the authorization granted by this article."

2. Issue of Warrants for the purpose of the Warrant Plan

- a) Acknowledgement of the special report of the Board of Directors and the report of the statutory auditor EY, Réviseurs d'Entreprises SRL, prepared in accordance with articles 7:180, 7:191 and 7:193 of the CAC, setting out the purpose and detailed justification of the proposal to issue warrants, with cancellation of the shareholders' preferential right, and with the option for the Board of Directors to, in the event of exercise, either allocate existing treasury shares or issue new shares (the "Warrants").
- b) **Proposal to issue** 250,000 Warrants, subject to the terms and conditions set out below, giving the right, subject to the effective allocation of these Warrants, to subscribe to an equivalent number of ordinary shares of the Company.

- c) **Proposal to cancel the preferential subscription right** of the existing shareholders in favor of the New Beneficiaries (as defined in the terms and conditions of the Warrants).
- d) Subject to the condition precedent of the exercise of the Warrants, and only to the extent the exercise of the Warrants results in the issue of new shares (as opposed to allocating treasury shares), proposal to increase the capital of the Company by an amount corresponding to the par value of the share, multiplied by the number of Warrants exercised, i.e. up to a maximum amount of EUR 153,073, with the issue of as many new shares as Warrants have been exercised, i.e. up to a maximum of 250,000 new shares, with the difference between the exercise price of the Warrant and the par value of the share constituting share premium.

<u>Proposed decision</u>: The general meeting decides to issue 250,000 Warrants, with the terms and conditions set out below, giving the right, subject to the effective allocation of these Warrants, to subscribe to an equivalent number of ordinary shares of the Company, with cancellation of the preferential subscription right of the existing shareholders in favor of the New Beneficiaries (as defined in the terms and conditions of the Warrants). Subject to the condition precedent of the exercise of the Warrants, and only to the extent the exercise of the Warrants results in the issue of new shares (as opposed to allocating treasury shares), the general meeting decides to increase the capital of the Company by an amount corresponding to the par value of the share, multiplied by the number of Warrants exercised, i.e. up to a maximum amount of EUR 153,073, with the issue of as many new shares as Warrants have been exercised, i.e. up to a maximum of 250,000 new shares, with the difference between the exercise price of the Warrant and the par value of the share constituting share premium

The general meeting confers powers to each two directors, acting jointly, to:

- specify (and, if necessary, have recorded in a notarial deed) the exact number of Warrants to be issued, the final exercise price of the Warrants, the exercise periods, the terms and conditions for adjusting the rights of the Warrants in the event of changes to the capital structure;
- have the completion of successive capital increases and the resulting amendments to the Articles of Association recorded in a notarial deed:
- execute the resolutions to be taken on the foregoing matters;
- for the above purposes, conclude all agreements and, in general, do whatever is necessary.

Terms and conditions of the issue of the Warrants:

Number of Warrants to be issued	Depending on the actual subscriptions and acquisitions, maximum two hundred and fifty thousand (250,000) Warrants.
Condition of the issue	Effective allocation of the Warrants to the New Beneficiaries.
Form of the Warrants	The Warrants are nominative and, once granted, recorded in the register of Warrant holders established by, and kept at the registered office of, the Company.
New Beneficiaries	To be determined by the Board of Directors among the staff members of the Company and its subsidiaries within the meaning of article 1:27 of the CAC as well as persons who, without being staff members of the Company or its subsidiaries, are either a permanent representative or partner or controlling shareholder of a staff member (a legal entity bound by a management or similar agreement), either bound to one of the companies of the EVS group by a contract for the provision of services of a consultancy type, or permanent representative or partner or controlling shareholder of a company linked to one of the companies of the EVS group by a contract for the provision of services of a consultancy type (hereinafter the "Providers"): InnoVision BV and its representative Serge Van Herck, WeMagine SRL and its representative Veerle De Wit, Openiris Ltd and its representative Alexander Redfern, Tols BV and its representative Xavier Orri Sáinz De Los Terreros, Ikaro SRL and its representative Pierre Matelart, RCG SRL and its representative Quentin Grutman, Euscopia.NET SRL and its representative Benoit Quirynen, Flashbackx Consultancy BV and its representative Dieter Backx, Coveloz Consulting Ltd and its representative Nestor Amaya, Manuel Alejandro Rios Ceron, Bruno Pessoa da Silva, Vegard Aandahl, Swapnil Almeida, Gustavo Bonfietti. Jeremy Bourque, Ana Martingano.

Price of the Warrants	Free of charge or against payment, under the conditions to be determined by the Board of Directors.
Granting Period of the Warrants	To be determined by the Board of Directors.
Number of Warrants to be offered per New Beneficiary	To be determined by the Board of Directors for each New Beneficiary.
Exercise price of the Warrants	(i) the average of the closing prices of the Company's shares for the 30 days preceding the grant, or (ii) the last closing price preceding the day of the grant based on the method that the Board of Directors deems most representative of the value of the Company's shares at the relevant time.
Warrant exercice period	The Warrants may only be exercised as from the fourth calendar year following the date of grant, on one or more dates and under the conditions to be determined by the Board of Directors, within the limits set by the EVS Corporate Governance Charter. This period will expire in any event no later than ten (10) years from the date of issue of the Warrants, in accordance with article 7:69 of the CAC.
Transfer of Warrants	Non-transferability inter vivos, except in case of (i) prior approval of the Board of Directors or (ii) transfer by a New Beneficiary in the form of a legal entity to its director or controlling shareholder who exercises a professional activity for the benefit of the Company or its subsidiaries.
Pledging of Warrants	Requires prior approval of the Board of Directors.
Rights conferred by the Warrants	Each Warrant entitles the holder to one newly issued share or one treasury share, at the discretion of the Board of Directors. The granted shares, whether new or existing (treasury), will have the same rights as all other outstanding shares.
Issue of new shares following the exercise of Warrants	In the event of an issue of new shares following the exercise of Warrants, the Company will issue them as soon as possible, taking into account the necessary administrative formalities. The Board of Directors or two directors authorized for this purpose shall confirm the resulting capital increase before a notary public, in accordance with the CAC. The Company shall arrange for the new shares issued as a result of the exercise of Warrants to be admitted to the market on which its shares are traded at the time of issue.
Right to dividends	Each share subscribed or acquired following the exercise of a Warrant will entitle its holder to the dividend declared after the date of allocation of the share.
Granting terms	The Board of Directors may determine the conditions for granting, retaining and exercising the Warrants.
Changes in the Company's capital structure	Notwithstanding Article 7:71 of the CAC, the Company can take all decisions it deems necessary within the framework of its capital or its articles of association, such as capital increases or reductions, the incorporation of reserves into the capital accompanied by the allocation of free shares, the issue of convertible bonds, bonds with warrants, other warrants or options, the distribution of dividends in the form of securities or the modification of the representation of the capital, as well as all decisions modifying the provisions governing the distribution of profits or liquidation surpluses, even if these decisions could have the effect of reducing the benefits granted to the Warrant holders, unless such decisions clearly have such a reduction as their exclusive objective. In the event of a merger or demerger of the Company, the Warrants not exercised at the date of such transaction, as well as the exercise price of such Warrants, will be modified in accordance with the exchange ratio applied to the existing shares of the Company in the context of such merger or demerger. In the event of a stock split or consolidation of the Company's shares, the number of shares to be received upon exercise of the Warrants will be adjusted accordingly to such stock split or consolidation.

In the event the Company carries out a capital increase by way of a contribution in cash before the final date foreseen for the exercise of the Warrants, the Warrant holders will not have the option to exercise their subscription right in advance in order to
possibly participate in the new issue as shareholders, to the extent that this right belongs to the existing shareholders
extent that this right belongs to the existing shareholders.

3. Powers to execute the decisions taken

<u>Proposed decision</u>: The general meeting confers on each member of the Board of Directors, with the right of substitution, all powers of execution of the decisions taken by the Extraordinary General Meeting. The general meeting gives the instruction to the undersigned Notary, acting alone, to draw up and sign the coordination of the Articles of Association, and to ensure its filing in the Company's file.

<u>Practical arrangements for attending the General Meetings</u>

The Board of Directors has not opted for the possibility of allowing shareholders to participate remotely to the General Meetings via electronic communication as offered by Article 7:137 of the CAC. However, it will allow shareholders to attend the Ordinary General Meeting by means of a videoconference or audioconference system, the details of which will be specified on the Company's website.

Formalities for admission

In order to attend and to vote at the General Meetings, shareholders are kindly requested to comply with article 7:134, §2 of the CAC as well as article 23, §1 of the Articles of Association of the Company:

- The owners of dematerialized shares must submit, for each General Meeting, a certificate drawn up by an accredited account holder or clearing institution
 - Attesting to the accounting registration of the shares in the name of the shareholders in the
 accounts of the accredited account holder or clearing institution as at May 2, 2023 at 12 (twelve)
 o'clock midnight, Belgian time (registration date),
 - o Indicating their intention to attend the General Meeting as well as the number of shares for which they intend to take part in the voting (accompanied by a power of attorney where appropriate),
 - And have this certificate reach the Company's registered office by May 10, 2023 at the latest (by registered letter with acknowledgement of receipt or by e-mail (corpcom@evs.com with acknowledgement of receipt or to the counter of an ING branch in Belgium (ING Issuer Services 60 Cours Saint Michel, 1040 Brussels +32 2 547 68 02 be-lfm.coa.spa@ing.be)).
- The owners of registered shares must be entered in the Company's register of registered shares as at May 2, 2023 at 12 (twelve) o'clock midnight, Belgian time (registration date), and must indicate their intention to attend the General Meeting as well as the number of shares for which they intend to take part in the voting (accompanied by a power of attorney where appropriate) by May 10, 2023 by sending a registered letter with acknowledgement of receipt to the Company's registered office or by e-mail (corpcom@evs.com) with acknowledgement of receipt.
- Holders of subscription rights may attend the General Meetings upon simple verification of their identity with regard to entries in the register of subscription rights, but they may only attend the General Meeting without taking part in the voting.

Right to enter new items on the agenda or proposals for resolution

Pursuant to article 7:130 of the CAC and article 22, §3 of the Articles of Association of the Company, one or more shareholders who together hold at least 3% of the capital may request to have items included on the agenda to be broached at the General Meetings and may submit proposals for resolutions on the items to be discussed which are included or to be included in the agenda. The request must be accompanied by the text of the items to be broached and the proposals for resolutions relating thereto, whereby the text of proposals for resolutions to be entered in the agenda must establish the ownership of the aforementioned fraction of the capital, and must indicate the postal or e-mail address to which the Company is to send the acknowledge of receipt of the request within forty-eight hours of such receipt. The request is to be sent by post to the registered office for the attention of Serge VAN HERCK, CEO, and must reach the Company by April 24, 2023 at the latest. The request may also be sent by e-mail (corpcom@evs.com).

An updated agenda, completed in accordance with any validly lodged requests, will be published by April 28, 2023 at the latest.

The examination of these new items to be broached and proposals for resolution is subject to the fulfilment of the afore-described admission formalities for at least 3% of the capital.

Right to ask questions

Pursuant to Article 7:139 of the CAC, shareholders who have complied with the aforementioned formalities for admission have the right to submit written questions to the Directors and/or the Auditor relating to items on the agenda as soon as this notice convening the meeting is published before the General Meetings.

These questions will be sent by registered letter with acknowledgement of receipt for the attention of Serge VAN HERCK, CEO or by e-mail (corpcom@evs.com) with acknowledgement of receipt. They must reach the Company by May 10, 2023 at the latest.

The Board of Directors will answer these questions in writing on the Company's website at the latest on the day of the General Meeting before the vote.

Voting by proxy

Shareholders who have fulfilled the afore-described formalities for admission may be represented by proxy using the form of power of attorney established by the Company.

The power of attorney must be given in writing or in electronic form, and must be signed by the shareholder, either in handwritten form or by an electronic signature process in accordance with applicable Belgian law.

The signed power of attorney must reach the Company no later than May 10, 2023, by e-mail (corpcom@evs.com) if signed by electronic signature, or by registered letter sent to the Company's registered office for the attention of Serge VAN HERCK, CEO. Any power of attorney not signed by the ultimate beneficial owner will be considered invalid.

Provision of documents

This convocation and the other documents relating to the General Meetings, including the annual report and the power of attorney forms are available on the Company's website www.evs.com from April 14, 2023. They may also be obtained by writing to EVS Broadcast Equipment SA, Corporate Relations, Liege Science Park, 13 Rue du Bois Saint-Jean, B-4102 Seraing or by e-mail to corpcom@evs.com.

The Board of Directors

ORDINARY GENERAL MEETING OF MAY 16, 2023 POWER OF ATTORNEY & VOTING FORM

To be returned by e-mail (corpcom@evs.com) or by registered letter to the Company's registered office

Any shareholder may be represented by a proxyholder. Shareholders who wish to be represented must comply with the practical arrangements set out in the notice convening the meeting. The duly signed power of attorney form must reach the Company by **May 10, 2023** at the latest.

THE UNDERSIGNED 1:
ADDRESS/ HEAD QUARTER:
Owner of
Or by default Mr. Nicolas Bayers

To whom it confers full powers to represent it at the Ordinary General Meeting of the Company to be held on **Tuesday May 16**, at **11:00** am at its registered office with the agenda set out in the appendix to this proxy.

Agenda:		Yes	No	Abstention
1. Acknowledgement	of the Management Report for year 2022	N/A	N/A	N/A
2. Approval of the Re	emuneration Report for year 2022			
3. Acknowledgement	of the Auditor's Reports for year 2022	N/A	N/A	N/A
the allocation of re	atutory and consolidated annual accounts 2022, sults and the profit-sharing plan in the form of a res to the Company's employees			
5. Discharge to the D	Directors			
6. Discharge to the A	auditor			
7. Renewal of Accom Cambier, as Direc	npany You SRL, represented by Mrs. Anne tor			
Appointment of Ini Herck, as Director	noVision BV, represented by Mr. Serge Van			
9. Appointment of FF Chandramouli, as	RINSO SRL, represented by Mrs. Soumya Director			
10. Approval of update	es to the Remuneration Policy	N/A	N/A	N/A
10.1 Remo	val of the remuneration of the executive			
10.2 Variab CTO, CXO an	le remuneration in cash of the CFO, CMO, CPO, d CCO			
10.3 Variab the CFO, CTC	le remuneration by way of grant of warrants to and CXO			
10.4 Variab of warrants to	le remuneration in cash of, and by way of grant, the CEO			
10.5 Proced	dure to allow deviations from the Remuneration			
11 Powers to execute	the decisions taken			

The proxyholder may in particular take part in all deliberations and vote on all proposals relating to the agenda and the foregoing effects, draw up and sign all deeds, documents, minutes, attendance list, elect official address for service, substitute and in general do whatever is necessary.

¹Legal entities must specify the name, first name and title of the natural person(s) who signs this letter on their behalf.

Shareholders who have cast their vote by returning this form duly signed to the Company may no longer vote at the Ordinary General Meeting of Shareholders for the number of votes thus cast. If the Company publishes an amended agenda of the Ordinary General Meeting of Shareholders in order to include new items or proposals for resolution at the request of one or more shareholders pursuant to Article 7:130 of the Belgian Companies and Associations Code, said form will remain valid for the items on the agenda it covers, provided that it has validly reached the Company before the publication of said amended agenda. The foregoing notwithstanding, the votes cast in this form on an item on the agenda will be null and void if the agenda was amended on that item to include a new proposal for resolution in accordance with Article 7:130 of the Belgian Companies and Associations Code. A proxy given for a meeting is valid for all subsequent meetings convened with the same agenda.

Done at	on	2023
The signature(s) must be preceded by the	handwritten words "Good for power	of attornev"

EXTRAORDINARY GENERAL MEETING OF MAY 16, 2023 POWER OF ATTORNEY & VOTING FORM

To be returned by e-mail (corpcom@evs.com) or by registered letter to the Company's registered office

Any shareholder may be represented by a proxyholder. Shareholders who wish to be represented must comply with the practical arrangements set out in the notice convening the meeting. The duly signed power of attorney form must reach the Company by **May 10, 2023** at the latest.

THE UNDERSIGNED 2:	
ADDRESS/ HEAD QUA	RTER:
whose registered office	
Or by default Mr. Nicola	s Bayers,

To whom it confers full powers to represent it at the Extraordinary General Meeting of the Company to be held on **Tuesday May 16 at 12:00 pm at its registered office**, before Maître France Andris, with the agenda set out in the appendix to this proxy.

Agenda:	Yes	No	Abstention
Authorised capital a) Acknowledgement of the special report of the Board of Directors	N/A	N/A	N/A
b) Authorization to the Board of Directors to increase the capital on one or more occasions up to a maximum amount of EUR 1,600,000, excluding the issue premium			
c) If proposal 1.b) does not obtain the required majority, authorization to the Board of Directors to increase the capital on one or more occasions up to a maximum amount of EUR 877,200, excluding the issue premium			
2. Issue of Warrants			
Powers to execute the decisions taken			

The proxyholder may in particular take part in all deliberations and vote on all proposals relating to the agenda and the foregoing effects, draw up and sign all deeds, documents, minutes, attendance list, elect official address for service, substitute and in general do whatever is necessary.

Shareholders who have cast their vote by returning this form duly signed to the Company may no longer vote at the Extraordinary General Meeting of Shareholders for the number of votes thus cast. If the Company publishes an amended agenda of the Extraordinary General Meeting of Shareholders in order to include new items or proposals for resolution at the request of one or more shareholders pursuant to Article 7:130 of the Belgian Companies and Associations Code, said form will remain valid for the items on the agenda it covers, provided that it has validly reached the Company before the publication of said amended agenda. The foregoing notwithstanding, the votes cast in this form on an item on the agenda will be null and void if the agenda was amended on that item to include a new proposal for resolution in accordance with Article 7:130 of the Belgian Companies and Associations Code. A proxy given for a meeting is valid for all subsequent meetings convened with the same agenda.

Done at	on	2023
The signature(s) must be preceded by the	e handwritten words "Good for p	ower of attorney"

²Legal entities must specify the name, first name and title of the natural person(s) who signs this letter on their behalf.